摘要
目的:探讨治疗前18F-FDG PET/CT显像在胆囊癌患者预后中的作用。方法:回顾2005年4月至2012年11月临床可疑胆囊癌并行18F-FDG PET/CT检查的95例患者,分析PET/CT显像及其他相关因素与患者预后之间的关系,研究PET/CT显像在评估胆囊癌预后中的价值。结果:Kaplan-Meier单因素分析显示A组(SUVmax值≤8.5)与B组(SUVmax值>8.5)患者的中位生存时间(266,166天)差异有统计学意义(P<0.05);PET/CT分期不同的患者之间的生存时间有显著性差异(P<0.05)。Cox多因素分析显示SUVmax值、术前血清CA19-9水平和治疗情况是本组患者生存预后的独立影响因素。结论:PET/CT分期及肿瘤原发部位的SUVmax值在评估胆囊癌患者预后方面具有一定的临床价值,能够指导临床尽早制定个体化治疗方案,提高胆囊癌的早期诊断率,可望延长患者生存期。
Objective： This study aimed to evaluate the role of 18F-FDG PET/CT imaging in predicting the prognosis of patients with gallbladder carcinoma. Methods： A total of 95 patients who were clinically suspected with gallbladder carcinoma from April 2005 to November 2012 were examined by 18F-FDG PET/CT. All cases were confirmed for gallbladder carcinoma; 68 cases were found to be pathological, and 27 were found to be long-term clinical follow-up cases. The relationship of PET/CT imaging date and other factors with the survival of the 95 patients with gallbladder carcinoma were retrospectively analyzed to evaluate the role of PET/CT imaging in the prognosis of patients with gallbladder carcinoma. Results： A total of 51 patients died and 44 patients survived out of the 95 patients with gallbladder carcinoma. Kaplan-Meier analysis showed that the survival time of patients in group A （SUVmax≤8.5） and group B （SUVmax〉8.5） was statistically different （266, 166） at P〈0.05. The survival time of patients belonging to different PET/CT staging was also statistically different at P〈0.05. Cox multi-factor analysis indicated （maximum standardized uptake values, SUVmax） that the preop-erative serum （CA19-9） level and treatment methods were all independent risk factors that prevented the long-term survival of the pa-tients. Conclusion： PET/CT staging and SUVmax of the primary tumor before treatment are important in estimating the prognosis of patients with gallbladder carcinoma. PET/CT staging and SUVmax can be utilized to set immediate individualized treatment, improve the curative effect, and extend the lifespan of patients with gallbladder carcinoma.
出处
《中国肿瘤临床》
CAS
CSCD
北大核心
2013年第7期410-413,共4页
Chinese Journal of Clinical Oncology
